Intellectual Property Office
July 1
12:00
2024
Paragraph | Update |
130.05.2 | Update to Authority to Act Order |
Paragraph | Update |
130.05.2 | Update to Authority to Act Order |
Paragraph | Update |
7.11.1 13.09 13.10.1 | Updated to in light of Thaler v Comptroller-General of Patents, Designs and Trade Marks [2023] UKSC 49 |
SPM3.03.1 | Updated in light of Newron Pharmaceuticals SpA v The Comptroller General of Patents, Trademarks and Designs [2024] EWCA Civ 128 |
SPM3.05.1 | Updated in light of Merck Serono S.A. v The Comptroller-General of Patents, Trade Marks and Designs [2023] EWHC 3240 (Ch) |
Paragraph | Update |
1.39.4 | Added in light of Emotional Perception AI Ltd v Comptroller-General of Patents, Designs and Trade Marks [2023] EWHC 2948 (Ch) |
3.87.3 | Updated in light of Teva Pharmaceutical Industries Ltd v Astellas Pharma Inc. [2022] EWHC 1316(Pat) and Teva Pharmaceutical Industries Ltd & Anor v Astellas Pharma Inc [2023] EWCA Civ 880 |
3.95 | Updated in light of Vernacare Limited v Moulded Fibre Products Limited [2023] EWCA Civ 831 |
76.15.5 | Updated in light of Philip Morris Products SA & Anor v Nicoventures Trading Ltd & Anor [2023] EWHC 2616 (Pat) |
76.20.1 | Added in light of Ensygnia v Shell [2023] EWHC 1495 (pat) |
SPC - Several paragraphs | Updated to reflect changes in terminology arising from the Retained EU Law (Revocation and Reform) Act 2023 |
Paragraph | Update |
20.02 | Updated in light of Walmart Apollos application BL O/0704/23 |
Paragraph | Update |
36.07 | Updated in light of Taylor v Lanarkshire Health Board (BL O/864/21) and (BL O/157/22) |
20.02 | Updated in light of Metabiotechs application BL O/359/23 |